Skip to main content
Deutsch

Clinical & Epidemiological Science Unit

Director: Assoc. Prof. Peter Mandl
  1. Department of Medicine III
  2. Our departments
  3. Rheumatology
  4. Research
  5. Clinical & Epidemiological Science Unit

Latest Research

Global Recruiting Patterns Affect Placebo Response Rates In Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis. June 2025

Collecting patient-reported outcomes via the COTIDIANA smartphone app: a prospective validity study. June 2025

Passive maternal immunity in children born to women with systemic autoimmune rheumatic disease - A case-control study. June 2025

Ultrasound in rheumatic and musculoskeletal diseases: from musculoskeletal to organ involvement. May 2025

Autoantibody development is associated with clinical severity of COVID-19: A cohort study May 2025

Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statement May 2025

Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases - a systematic literature review informing the 2024 update of an international expert consensus statement May 2025

Rheumatoid arthritis before rheumatoid arthritis: What can we learn from clinical trials? April 2025

Role of rheumatoid arthritis registries worldwide: What have they taught us? March 2025

Autoantibody development is associated with clinical severity of COVID-19: A cohort study. March 2025

Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update. March 2025

How to treat undifferentiated arthritis today or tomorrow? A consideration of treatment recommendations in light of current evidence. February 2025

Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases-a systematic literature review informing the 2024 update of an international expert consensus statement. Feburary 2025

Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases-a systematic literature review informing the 2024 update of an international expert consensus statement. February 2025

Research Group of Helga Lechner-Radner

To the Research Group

Research Group of Peter Mandl

We perform and interpret imaging studies encompassing all manifestations of rheumatic and musculoskeletal diseases and develop new diagnostic and therapeutic methods targeting fibroblasts.

To the research group

Research Group of Clemens Scheineker

Autoimmunity and Immunodeficiency

We study, treat and manage patients with immune mediated inflammatory diseases as well as patients with primary or secondary immunodeficiencies.

To the Research Group

Research Group of Daniela Sieghart

Biomarkers in rheumatic disorders

We study autoantibodies as potential biomarkers for diagnosis, management and prognosis of rheumatic conditions.

To the Research Group

Research Group of Paul Studenic

We try to understand the validity of outcomes used in measuring disease activity, progression, quality of life and the interaction of patients with the health care system.

To the Research Group